Description: Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally. It provides active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, triamine, diacetyl guanine, guanine, and diacetylacyclovir; organic chemical raw materials comprising fluoride salts, glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. The company was founded in 2002 and is headquartered in Huanggang, China.
Home Page: www.hbhypharm.com
No.8 Hongyuan Road
Huanggang,
China
Phone:
86 71 3507 2024
Officers
| Name | Title |
|---|---|
| Mr. Shuangxi Xu | Director and General Manager |
| Mr. Kefeng Zeng | Financial Director |
| Mr. Yonghua Xiao | Director |
| Mr. Zhihua Deng | Deputy GM & Non-Independent Director |
| Mr. Siyuan Cheng | Deputy GM & Non-Independent Director |
Exchange: SHE
Country: CN : China
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 255 |
| Price-to-Book MRQ: | 1.4558 |
| Price-to-Sales TTM: | 3.3657 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2075 |